AnaptysBio - ANAB Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings or view top-rated stocks.

5 equities research analysts have issued 12-month price targets for AnaptysBio's shares. Their ANAB share price forecasts range from $24.00 to $35.00. On average, they anticipate the company's share price to reach $29.25 in the next twelve months. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts.

AnaptysBio's stock was trading at $34.75 at the beginning of 2022. Since then, ANAB shares have decreased by 26.9% and is now trading at $25.41.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ANAB earnings forecast.

AnaptysBio, Inc. (NASDAQ:ANAB) posted its quarterly earnings data on Monday, August, 8th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by $0.20. The biotechnology company had revenue of $1.22 million for the quarter, compared to analysts' expectations of $6.35 million. AnaptysBio had a negative net margin of 448.43% and a negative trailing twelve-month return on equity of 31.00%.

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

AnaptysBio's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (8.16%), State Street Corp (4.09%), Woodline Partners LP (3.26%), Point72 Asset Management L.P. (3.02%), Deerfield Management Company L.P. Series C (2.73%) and Assenagon Asset Management S.A. (2.44%). Insiders that own company stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends.

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANAB stock can currently be purchased for approximately $25.41.

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $717.58 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57,800,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

The company employs 102 workers across the globe.

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.